Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis.
Although statin treatment leads consistently to a reduction in major adverse coronary events and death in clinical trials, approximately 60 to 70% residual risk of these outcomes still remains. One frontier of investigational drug research is treatment to increase HDL, the 'good cholesterol' that is associated with a reduced risk of coronary artery disease. HDL and its major protein apolipoprotein A-I (apoAI) are protective against atherosclerosis through several mechanisms, including the ability to mediate reverse cholesterol transport. This review focuses on the preclinical and clinical findings for two types of therapies for the treatment of atherosclerosis: apoAI-containing compounds and apoAI mimetic peptides. Both of these therapies have excellent potential to be useful clinically to promote atherosclerosis regression and stabilize existing plaques, but significant hurdles must be overcome in order to develop these approaches into safe and effective therapies.
Smith
Jonathan D
JD
Cleveland Clinic, Department of Cell Biology, 9500 Euclid Avenue, Cleveland, OH 44195, USA. smithj4@ccf.org
D000818:Animals; D016632:Apolipoprotein A-I / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000188:drug therapy*; D008076:Cholesterol, HDL / Q000378:metabolism; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000517:prevention & control; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D008075:Lipoproteins, HDL / Q000008:administration & dosage / Q000097:blood* / Q000494:pharmacology / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use*; D040242:Risk Reduction Behavior
D016632:Apolipoprotein A-I; D008076:Cholesterol, HDL; D008075:Lipoproteins, HDL; D010455:Peptides